gutflix
GI learning, personalised

Summary

LONG-TERM OUTCOMES OF ORAL ANTIBIOTICS COMBINATION THERAPY FOR INDUCTION AND MAINTENANCE OF ULCERATIVE COLITIS

Toshifumi Ohkusa

UEG Week Copenhagen 2023 | Poster

IBD

October 15, 2023

A prospective open-label trial of 311 active ulcerative colitis patients showed that a 2-week combination antibiotic therapy (amoxicillin, tetracycline, metronidazole) achieved response rates of 75.2% at completion and 35.4% at 12 months, with a 95.7% compliance rate.

KEY POINTS

- The response rate was 75.2% at completion of the 2-week treatment, 62.7% at 3 months, and 35.4% at 12 months; remission rates were 30.9%, 29.6%, and 24.4% at the same time points respectively.
- Patients with severe disease activity showed statistically higher response rates at 6 months (p=0.0299), while response rates showed no statistical difference by steroid dependence, resistance, or disease extent.
- Adverse events occurred in 60.8% of participants, most commonly diarrhea (19.0%) and fever (14.8%), with no life-threatening events and all symptoms resolving after discontinuation or completion of therapy.
- The treatment regimen consisted of oral amoxicillin 1500mg, tetracycline 1500mg, and metronidazole 750mg daily for 2 weeks, added to conventional medication, with a compliance rate of 95.7%.
- This material is relevant to gastroenterologists managing ulcerative colitis patients and considering antibiotic-based adjunctive therapies.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/50dac91a-743c-11ee-9ae2-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.